Mylan Launches Generic Version of Prandin in U.S.

Mylan (NASDAQ: MYL  ) is shipping out a new generic version of a branded treatment. The company announced today that its American subsidiary, Mylan Pharmaceuticals, has begun the sale of Repaglinide, the generic form of Novo Nordisk's (NYSE: NVO  ) Prandin, in the U.S. market. Repaglinide tablets are sold in 0.5 milligram, 1 milligram, and 2 milligram configurations.

Repaglinide/Prandin is a treatment described by Mylan as "an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

Mylan is one of the more prominent generic producers on the market. Although the value of branded drugs losing patent protection dropped by around $25 billion to hit $30 billion in 2013, that number is expected to rise to $34 billion this year and balloon to $66 billion in 2015.  


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2807263, ~/Articles/ArticleHandler.aspx, 4/16/2014 6:36:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement